[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.139.136. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Review
November 4, 1998

Endovaginal Ultrasound to Exclude Endometrial Cancer and Other Endometrial Abnormalities

Author Affiliations

From the General Internal Medicine Section, San Francisco Veterans Affairs Medical Center, San Francisco, Calif (Drs Smith-Bindman, Kerlikowske, and Grady); Departments of Radiology (Drs Smith-Bindman, Scheidler, and Feldstein), Epidemiology and Biostatistics (Drs Kerlikowske, Segal, Brand, and Grady), and Obstetrics, Gynecology, and Reproductive Sciences (Dr Subak), University of California, San Francisco. Dr. Scheidler is now with the Department of Diagnostic Radiology, University of Munich, Munich, Germany.

JAMA. 1998;280(17):1510-1517. doi:10.1001/jama.280.17.1510
Context.—

Context.— Postmenopausal vaginal bleeding is a common clinical problem. Endovaginal ultrasound (EVUS) is a noninvasive diagnostic test that may help determine which women should undergo endometrial biopsy.

Objective.— To determine the accuracy of EVUS in detecting endometrial disease in postmenopausal women with vaginal bleeding according to hormone replacement use.

Data Sources.— Literature search of English-language and non–English-language articles published from 1966 through November 1996 using MEDLINE and by a manual search of bibliographies of published articles.

Study Selection.— Studies were included if they prospectively collected EVUS measurements of endometrial thickness prior to obtaining endometrial tissue for histologic evaluation in postmenopausal women with vaginal bleeding. Of 85 studies that included data on EVUS and endometrial histology, 35 were included in the meta-analysis and included 5892 women.

Data Extraction.— Articles were reviewed and independently selected and abstracted by 2 reviewers. Disagreement was resolved by consensus.

Data Synthesis.— The overall summary mean weighted estimates of sensitivity and specificity were calculated for thresholds of endometrial thickness from 3 to 10 mm. Using a 5-mm threshold to define abnormal endometrial thickening, 96% (95% confidence interval [CI], 94%-98%) of women with cancer had an abnormal EVUS result, whereas 92% (95% CI, 90%-93%) of women with endometrial disease (cancer, polyp, or atypical hyperplasia) had an abnormal result. This did not vary by hormone replacement use. However, the number of women with normal histology who had an abnormal EVUS result did vary by hormone replacement use. In women who were not using hormone replacement therapy, 593 (8%) with normal histological findings had an abnormal EVUS result (specificity, 92%; 95% CI, 90%-94%), whereas 1544 (23%) using hormone replacement therapy had an abnormal EVUS result (specificity, 77%; 95% CI, 75%-79%). For a postmenopausal woman with vaginal bleeding with a 10% pretest probability of endometrial cancer, her probability of cancer is 1% following a normal EVUS result.

Conclusion.— Endovaginal ultrasound has a high sensitivity for detecting endometrial cancer and other endometrial disease and can reliably identify postmenopausal women with vaginal bleeding who are highly unlikely to have significant endometrial disease so that endometrial sampling may be unnecessary.

×